Diagnostic accuracy of two-dimensional shear wave elastography and point shear wave elastography in identifying different stages of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: A meta-analysis

Saved in:
Bibliographic Details
Title: Diagnostic accuracy of two-dimensional shear wave elastography and point shear wave elastography in identifying different stages of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: A meta-analysis
Authors: Xiangyi Xu, Yiqing Zhang, Qiwei Zhu, Yuchen Xie, Yuanyuan Zhou, Bingtian Dong, Chaoxue Zhang
Source: Biomol Biomed
Biomolecules & Biomedicine (2025)
Publisher Information: Association of Basic Medical Sciences of FBIH, 2025.
Publication Year: 2025
Subject Terms: 2-D SWE, Liver Cirrhosis, MASLD, QH301-705.5, point shear wave elastography, metabolic dysfunction-associated steatotic liver disease, Fatty Liver, ROC Curve, Two-dimensional shear wave elastography, Elasticity Imaging Techniques, Humans, Biology (General), pSWE, Meta-Analysis
Description: To assess the diagnostic accuracy of two-dimensional shear wave elastography (2-D SWE) and point shear wave elastography (pSWE) in detecting liver fibrosis stages in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), a comprehensive search was conducted across four databases up to February 9, 2024. A bivariate random-effects model was used to analyze the diagnostic accuracy of the methods. After screening, 13 studies involving pSWE included 1527 patients, while nine studies involving 2-D SWE included 1088 patients. The areas under the summary receiver operating characteristic (SROC) curves for diagnosing significant fibrosis (F ≥ 2), advanced fibrosis (F ≥ 3), and cirrhosis (F = 4) using pSWE and 2-D SWE were as follows: 0.84 (95% CI 0.80–0.87), 0.91 (95% CI 0.88–0.93), and 0.94 (95% CI 0.91–0.95) for pSWE; 0.83 (95% CI 0.79–0.86) 0.85 (95% CI 0.82–0.88), and 0.89 (95% CI 0.86–0.91) for 2-D SWE, respectively. The pooled sensitivity for pSWE and 2-D SWE for stages F ≥ 2, F ≥ 3, and F = 4 were 0.71 (95% CI 0.63–0.78), 0.81 (95% CI 0.72–0.88), and 0.81 (95% CI 0.63–0.91) for pSWE, and 0.77 (95% CI 0.68–0.84), 0.80 (95% CI 0.72–0.87), and 0.92 (95% CI 0.75–0.98) for 2-D SWE, respectively. The pooled specificity of pSWE and 2-D SWE for these stages were 0.83 (95% CI 0.76–0.88), 0.87 (95% Cl: 0.81–0.92), and 0.91 (95% CI 0.86–0.94) for pSWE, and 0.76 (95% CI 0.66–0.84), 0.76 (95% CI 0.69–0.82), and 0.83 (95% CI 0.78–0.85) for 2-D SWE, respectively. In conclusion, both 2-D SWE and pSWE demonstrated high diagnostic performance in identifying various stages of liver fibrosis in MASLD patients.
Document Type: Article
Other literature type
ISSN: 2831-090X
2831-0896
DOI: 10.17305/bb.2024.11577
Access URL: https://pubmed.ncbi.nlm.nih.gov/39831901
https://doaj.org/article/449349ed086e48aab0cb35b4c9c3a8fe
Rights: CC BY
URL: http://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at http://creativecommons.org/licenses/by/4.0/).
Accession Number: edsair.doi.dedup.....e31323617a783663f0162a2f45231825
Database: OpenAIRE
Description
Abstract:To assess the diagnostic accuracy of two-dimensional shear wave elastography (2-D SWE) and point shear wave elastography (pSWE) in detecting liver fibrosis stages in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), a comprehensive search was conducted across four databases up to February 9, 2024. A bivariate random-effects model was used to analyze the diagnostic accuracy of the methods. After screening, 13 studies involving pSWE included 1527 patients, while nine studies involving 2-D SWE included 1088 patients. The areas under the summary receiver operating characteristic (SROC) curves for diagnosing significant fibrosis (F ≥ 2), advanced fibrosis (F ≥ 3), and cirrhosis (F = 4) using pSWE and 2-D SWE were as follows: 0.84 (95% CI 0.80–0.87), 0.91 (95% CI 0.88–0.93), and 0.94 (95% CI 0.91–0.95) for pSWE; 0.83 (95% CI 0.79–0.86) 0.85 (95% CI 0.82–0.88), and 0.89 (95% CI 0.86–0.91) for 2-D SWE, respectively. The pooled sensitivity for pSWE and 2-D SWE for stages F ≥ 2, F ≥ 3, and F = 4 were 0.71 (95% CI 0.63–0.78), 0.81 (95% CI 0.72–0.88), and 0.81 (95% CI 0.63–0.91) for pSWE, and 0.77 (95% CI 0.68–0.84), 0.80 (95% CI 0.72–0.87), and 0.92 (95% CI 0.75–0.98) for 2-D SWE, respectively. The pooled specificity of pSWE and 2-D SWE for these stages were 0.83 (95% CI 0.76–0.88), 0.87 (95% Cl: 0.81–0.92), and 0.91 (95% CI 0.86–0.94) for pSWE, and 0.76 (95% CI 0.66–0.84), 0.76 (95% CI 0.69–0.82), and 0.83 (95% CI 0.78–0.85) for 2-D SWE, respectively. In conclusion, both 2-D SWE and pSWE demonstrated high diagnostic performance in identifying various stages of liver fibrosis in MASLD patients.
ISSN:2831090X
28310896
DOI:10.17305/bb.2024.11577